EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access

A prospective head-to-head comparison of [68Ga]Ga-P16-093 and [68Ga]Ga-PSMA-11 PET/CT in patients with primary prostate cancer

Guochang Wang, Linlin Li, Ming Zhu, Jie Zang, Jiarou Wang, Rongxi Wang, Weigang Yan, Lin Zhu, Hank F Kung, Zhaohui Zhu

European Journal of Nuclear Medicine and Molecular Imaging · 2023

DOI: 10.1007/s00259-023-06283-4 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2023. Verfasst von Guochang Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and …. Hauptthemen laut MEDLINE: Gallium Radioisotopes, Prostatic Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: the National High Level Hospital Clinical Research Funding, the Fundamental Research Funds for the Central Universities, Chinese Academy of Medical Science Innovation Fund for Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: We aimed to compare the diagnostic performance and biodistribution of two similar PET agents, [68Ga]Ga-P16-093 and [68Ga]Ga-PSMA-11, in the same group of primary prostate cancer (PCa) patients. METHODS: Fifty patients with untreated, histologically confirmed PCa by needle biopsy were enrolled. Each patient underwent [68Ga]Ga-P16-093 and [68Ga]Ga-PSMA-11 PET/CT within a week. In addition to visual analysis, the standardized uptake value (SUV) was measured for semiquantitative comparison and correlation analysis. RESULTS: [68Ga]Ga-P16-093 PET/CT detected more positive tumors than [68Ga]Ga-PSMA-11 PET/CT (202 vs. 190, P = 0.002), both for intraprostatic lesions (48 vs. 41, P = 0.016) and metastatic lesions (154 vs. 149, P = 0.125), especially for intraprostatic lesions in low- and intermediate-risk PCa patients (21/23 vs. 15/23, P = 0.031). Furthermore, [68Ga]Ga-P16-093 PET/CT exhibited a significantly higher SUVmax for most matched tumors (13.7 ± 10.2 vs. 11.4 ± 8.3, P < 0.001). For normal organs, [68Ga]Ga-P16-093 PET/CT showed significantly lower activity in the kidney (SUVmean: 20.1 ± 6.1 vs. 29.3 ± 9.1, P < 0.001) and urinary bladder (SUVmean: 6.5 ± 7.1 vs. 20.9 ± 17.4, P < 0.001), but displayed a higher uptake in the parotid gland (SUVmean: 8.7 ± 2.6 vs. 7.6 ± 2.1, P < 0.001), liver (SUVmean: 7.0 ± 1.9 vs. 3.7 ± 1.3, P < 0.001), and spleen (SUVmean: 8.2 ± 3.0 vs. 5.2 ± 2.2, P < 0.001) than [68Ga]Ga-PSMA-11 PET/CT. CONCLUSION: [68Ga]Ga-P16-093 PET/CT demonstrated higher tumor uptake and better tumor detectability than [68Ga]Ga-PSMA-11 PET/CT, especially in low- and intermediate-risk PCa patients, which indicated that [68Ga]Ga-P16-093 may serve as an alternative agent for detection of PCa. TRIAL REGISTRATION: 68Ga-P16-093 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Primary Prostate Cancer Patients (NCT05324332, Registered 12 April 2022, retrospectively registered). URL OF REGISTRY: https://clinicaltrials.gov/ct2/show/NCT05324332 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gallium RadioisotopesProstatic NeoplasmsHumansMaleEdetic AcidPositron Emission Tomography Computed TomographyProspective StudiesTissue Distribution

Stichwörter der Autor:innen

PET/CTProstate cancer[68Ga]Ga-P16-093[68Ga]Ga-PSMA-11

Substanzen

Edetic AcidGallium RadioisotopesPSMA-11

Autor:innen und Institutionen

  • Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Ch…
  • Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100730, China.
  • Department of Nuclear Medicine, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350005, China.
  • Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, 100730, China. ywgpumch@sina.com.
  • College of Chemistry, Key Laboratory of Radiopharmaceuticals, Ministry of Education, Beijing Normal University, Beijing, 100875, China. zhulin@bnu.edu.cn.
  • Department of Radiology, University of Pennsylvania, Philadelphia, PA, 19104, USA. kunghf@sunmac.spect.upenn.edu.

Förderung

  • the National High Level Hospital Clinical Research Funding
  • the Fundamental Research Funds for the Central Universities
  • Chinese Academy of Medical Science Innovation Fund for Medical Sciences
  • Beijing Natural Science Foundation
  • the National Natural Science Foundation of China

Zitieren

APA

Wang, G., Li, L., Zhu, M., Zang, J., Wang, J., Wang, R., Yan, W., Zhu, L., Kung, H. F., & Zhu, Z. (2023). A prospective head-to-head comparison of [68Ga]Ga-P16-093 and [68Ga]Ga-PSMA-11 PET/CT in patients with primary prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-023-06283-4

Vancouver

Wang G, Li L, Zhu M, Zang J, Wang J, Wang R, et al. A prospective head-to-head comparison of [68Ga]Ga-P16-093 and [68Ga]Ga-PSMA-11 PET/CT in patients with primary prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2023. doi:10.1007/s00259-023-06283-4

BibTeX
@article{Wang2023,
  author = {Wang, Guochang and Li, Linlin and Zhu, Ming and Zang, Jie and Wang, Jiarou and Wang, Rongxi and Yan, Weigang and Zhu, Lin and Kung, Hank F and Zhu, Zhaohui},
  title = {A prospective head-to-head comparison of [68Ga]Ga-P16-093 and [68Ga]Ga-PSMA-11 PET/CT in patients with primary prostate cancer},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2023},
  doi = {10.1007/s00259-023-06283-4}
}
Kostenlos starten →